Security
CLDWW · Calidi Biotherapeutics, Inc.
CLDWWOTCWarrantCurrentCIK 1855485Updated Sep 24, 2026
Name history
Calidi Biotherapeutics, Inc. · through Sep 22, 2026First Light Acquisition Group, Inc. · through Sep 19, 2023
CLDWW price & chart
Derivative provider spelling needs an explicit mapping.
About the company
We are a clinical stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses. We are currently developing RedTail, an enveloped vaccinia virus platform designed to deliver genetic medicine to tumor sites, and two proprietary stem cell-based oncolytic virus platforms (SuperNova and NeuroNova). The RedTail platform is expected to open an IND by the end of 2026 with the first compound (CLD-401) delivering IL-15 superagonist to the tumor microenvironment (“TME”).
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
4 filing
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,857,000Source | 14,182,000Source | 10,019,000Source | 42,854,778Source |
| Property, Plant and Equipment, NetUSD | 781,000Source | 869,000Source | 1,270,000Source | 1,270,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 9,600,000Source | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 870Source |
| Assets, CurrentUSD | 6,256,000Source | 10,227,000Source | 4,303,000Source | 401,671Source |
| Prepaid Expense and Other Assets, CurrentUSD | 656,000Source | 636,000Source | 2,354,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 1,682,000Source | 2,934,000Source | 4,073,000Source | — |
| Other Assets, NoncurrentUSD | 138,000Source | 152,000Source | 143,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,098,000Source | 12,214,000Source | 18,254,000Source | 5,607,147Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 2,000Source | 4,000Source | — |
| Additional Paid in CapitalUSD | 145,392,000Source | 123,275,000Source | 91,380,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -141,621,000Source | -121,715,000Source | -99,572,000Source | -5,206,051Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -13,000Source | -28,000Source | -47,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 3,759,000Source | 1,534,000Source | -8,235,000Source | -5,205,476Source |
| Liabilities and EquityUSD | 8,857,000Source | 14,182,000Source | 10,019,000Source | 42,854,778Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,935,000Source | 9,496,000Source | 10,232,000Source | 4,535,913Source |
| Operating Lease, Liability, CurrentUSD | 1,405,000Source | 1,204,000Source | 1,035,000Source | — |
| Accounts Payable, CurrentUSD | — | — | — | 51,074Source |
| Operating Lease, Liability, NoncurrentUSD | 277,000Source | 1,845,000Source | 3,037,000Source | — |
| Other Liabilities, NoncurrentUSD | — | — | 1,500,000Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | 434,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 3,219,620Source |
| Long-term DebtUSD | 600,000Source | 600,000Source | 2,060,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 90,000Source | 3,221,000Source | 807,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -20,063,000Source | -22,209,000Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,108,000Source | 2,957,000Source | 4,809,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | 870Source |
| Increase (Decrease) in Accounts PayableUSD | -1,328,000Source | -628,000Source | -6,170,000Source | -12,765Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -21,293,000Source | -19,694,000Source | -26,983,000Source | 98,051Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -170,000Source | -16,000Source | -478,000Source | 187,686,217Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 17,459,000Source | 27,365,000Source | 29,044,000Source | -188,753,029Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,990,000Source | 7,642,000Source | — | -968,761Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,819,000Source | 9,809,000Source | 2,167,000Source | 93,892Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,265,000Source | 140,000Source | 404,000Source | — |
| Income Taxes Paid, NetUSD | 17,000Source | 14,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,000Source | -13,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,108,000Source | 2,957,000Source | 4,809,000Source | — |
| DepreciationUSD | — | 402,000Source | 392,000Source | — |
| Other Depreciation and Amortization | — | — | — | — |
| Income Tax Expense (Benefit)USD | 15,000Source | 14,000Source | 16,000Source | 346,987Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 134,540Source |
| Net Income (Loss) Attributable to ParentUSD | -19,906,000Source | -22,143,000Source | -29,216,000Source | 3,530,190Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -157,000Source | -66,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,579,000Source | -23,814,000Source | — | 1,071,338Source |
| Nonoperating Income (Expense)USD | 192,000Source | -419,000Source | -208,000Source | 8,546,701Source |
| Operating ExpensesUSD | 20,240,000Source | 21,776,000Source | 28,992,000Source | 4,669,524Source |
| Other Nonoperating Income (Expense)USD | 103,000Source | 9,000Source | -51,000Source | — |
| Payments of Financing CostsUSD | 846,000Source | 1,554,000Source | 2,156,000Source | — |
| Payments to Acquire InvestmentsUSD | 50,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 281,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 10,503,000Source | 12,898,000Source | 15,984,000Source | — |
| Operating Income (Loss)USD | -20,240,000Source | -21,776,000Source | -28,992,000Source | -4,669,524Source |
| Other Nonoperating Income (Expense)USD | 103,000Source | 9,000Source | -51,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -20,048,000Source | -22,195,000Source | -29,200,000Source | 3,877,177Source |
| Income Tax Expense (Benefit)USD | 15,000Source | 14,000Source | 16,000Source | 346,987Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -157,000Source | -66,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -19,906,000Source | -22,143,000Source | -29,216,000Source | 3,530,190Source |
| Earnings Per Share, BasicUSD per share | -5.95Source | -2.97Source | 1.73Source | — |
| Earnings Per Share, DilutedUSD per share | -5.95Source | -2.97Source | 1.73Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,302Source | 8,005,000Source | 16,887,000Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,302Source | 8,005,000Source | 16,887,000Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 15,000Source | 14,000Source | 16,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,651,000Source | — | — | — |
| Interest Expense, DebtUSD | 100,000Source | 700,000Source | 1,100,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,579,000Source | -23,814,000Source | — | 1,071,338Source |
| Nonoperating Income (Expense)USD | 192,000Source | -419,000Source | -208,000Source | 8,546,701Source |
| Operating ExpensesUSD | 20,240,000Source | 21,776,000Source | 28,992,000Source | 4,669,524Source |
| Research and Development ExpenseUSD | 9,737,000Source | 8,878,000Source | 13,008,000Source | — |
Offerings
Registration 333-289670
- Gross proceeds
- 6000000.0
- Net proceeds
- 5460000.0
- Deal price
- 2.0
- Shares
- 3000000
- Offering price
- $2.00
- Ticker
- CLDI
Registration 333-288529
Filing attachments
ex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering SAN DIEGO, September 17, 2026 - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s comm…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph. D., to Board of Directors Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of…
Read attachment ↗ex4-1.htm · 8-K · 2026-05-29
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo…
Read attachment ↗ex4-1.htm · 8-K · 2026-05-08
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗